Lacto-N-tetraose (LNT) is a primary neutral Human Milk Oligosaccharide (HMO) and the defining Type I core structure, characterized by the tetrasaccharide sequence Gal(β1-3)GlcNAc(β1-3)Gal(β1-4)Glc. Unlike the type II isomer (LNnT), LNT is the most abundant core tetrasaccharide in human breast milk, often serving as the quantitative benchmark for "humanizing" infant formula. LNT plays a dual role in neonatal development: it acts as a highly selective prebiotic for Bifidobacterium longum subsp. infantis and serves as a metabolic precursor for more complex fucosylated and sialylated HMOs. CD BioGlyco provides an industry-leading LNT production service utilizing advanced Synthetic Glycobiology. Our platform bypasses the prohibitive costs of chemical synthesis and the ethical limitations of bovine milk extraction, delivering bio-identical LNT with high purity and industrial scalability.
Core Technologies
We employ a sophisticated metabolic engineering suite to optimize LNT biosynthesis:
Regioselective Glycosyltransferase Engineering
We utilize a dual-enzyme module featuring β-1,3-N-acetylglucosaminyltransferase (LgtA) and β-1,3-galactosyltransferase (e.g., WbgO or CpsD) to ensure the precise formation of the Type I backbone.
Nucleotide Sugar Flux Management
Our microbial chassis are refactored to overexpress the glmS-glmM-glmU pathway for UDP-GlcNAc and the galETKM cluster for UDP-Gal, ensuring saturating levels of donor substrates.
Degradation Pathway Silencing
To maximize titer, we perform genomic deletions of endogenous β-galactosidases (lacZ) and N-acetylglucosamine-6-phosphate deacetylases (nagA/nagB), preventing the breakdown of LNT intermediates.
Modular Pathway Integration
We utilize markerless, multicopy chromosomal integration to stabilize the biosynthetic pathway, eliminating the need for antibiotic selection and ensuring plasmid stability during large-scale fermentation.
Precision Glycobiology for the Golden Standard of HMO
The LNT production service provides a total solution for clients requiring high-purity LNT for research and industrial applications. Our scope of service is built on a foundation of scientific excellence and regulatory readiness. We offer custom strain engineering, allowing for the development of bespoke microbial cell factories that are optimized for specific production environments or proprietary feedstocks. Our process development division works closely with partners to scale up production from milligram-scale laboratory pilots to multi-kilogram industrial batches, ensuring a seamless transition from R&D to market.
In addition to core manufacturing, our service scope includes HMO blend formulation support, where we assist clients in creating precise ratios of LNT with other glycans like 2'-FL or 6'-SL to mimic the "Secretor" or "Non-secretor" profiles. We provide analytical reference standards of the highest quality for quantitative glycomics, as well as regulatory compliance documentation to support novel food or GRAS research. Our service is designed to be a "Sub-page entry" into the broader world of synthetic glycobiology, offering options for isotope labeling (13C/15N) for metabolic tracing studies. Whether you are conducting fundamental microbiome research or formulating the next generation of premium infant nutrition, we provide the technical depth and manufacturing reliability to secure your supply chain.
Workflow
Chassis Design & Optimization
We initiate our process with the strategic selection and engineering of a dedicated microbial host. Typically, we utilize a highly domesticated and well-characterized derivative of E. coli K-12 for its genetic tractability and safety profile. The core of this stage is a systematic metabolic "rewiring" of the selected chassis. Using tools from systems biology and constraint-based modeling, we identify and inactivate key nodes in central carbon metabolism that compete for precursors essential for glycan biosynthesis. This involves targeted gene knockouts (e.g., in pathways for lactate, acetate, or ethanol formation) to minimize byproduct secretion and reroute intracellular carbon flux away from biomass accumulation and toward the nucleotide sugar donors (UDP-Gal, UDP-GlcNAc) required for efficient LNT synthesis.
Pathway Assembly & Tuning
The complete LNT biosynthetic pathway is constructed from synthetic, codon-optimized gene clusters. These clusters encode the specific β-1,3-galactosyltransferase (responsible for adding the second galactose to lacto-N-triose II) and the necessary suite of enzymes for the de novo synthesis and regeneration of UDP-sugar donors. This entire assembly is stably integrated into the host's genome using high-precision techniques like CRISPR-Cas9. Post-integration, we engage in iterative fine-tuning. Using libraries of tunable promoters and ribosomal binding sites, we meticulously balance the expression ratios between the donor-sugar synthesis modules and the glycosyltransferase. This critical balance minimizes the accumulation of the metabolic intermediate lacto-N-triose II, ensuring optimal flux is directed toward the complete, target LNT molecule.
High-Titer Fermentation
LNT production is scaled through a robust, high-cell-density fed-batch fermentation protocol. We operate across a validated scale of bioreactors from 10L (process development) to 1,000L (pilot production). The fermentation strategy is focused on maximizing the space-time yield (g/L/h). This is achieved by continuously optimizing two critical parameters: the oxygen transfer rate (OTR), controlled via agitation and aeration, and a dynamic substrate feeding profile. We employ a dual-substrate feed, carefully controlling the ratio and feed rate of glucose (for growth and energy) and lactose (the acceptor molecule). This approach maintains the cells in a prolonged, high-productivity phase, enabling the achievement of maximum LNT titers suitable for commercial-scale production.
Refined Downstream Recovery
The recovery of high-purity LNT from the fermentation broth is accomplished through a sophisticated, multi-step purification sequence. The process begins with centrifugal separation for cell harvest, followed by depth filtration or microfiltration for primary clarification. The clarified broth then undergoes ultrafiltration/diafiltration (UF/DF) to remove host cell proteins, endotoxins, and other high-molecular-weight impurities while simultaneously concentrating the product stream. The core purification is achieved using preparative high-performance liquid chromatography (HPLC), specifically employing size-exclusion or ligand-based affinity columns designed for high-resolution separation of LNT from structurally similar residual sugars and process-related impurities.
Structural Validation
Each production batch is subjected to a rigorous, dual-faceted analytical validation to guarantee its identity and quality. First, liquid chromatography-mass spectrometry (LC-MS) is used to confirm the exact molecular mass of LNT and to perform a quantitative purity assessment, detecting any trace contaminants or isomers. Conclusive structural proof is provided by proton nuclear magnetic resonance (1H-NMR) spectroscopy. This technique definitively confirms the presence and configuration of the specific β-1,3-linkage between galactose and N-acetylglucosamine that defines LNT, distinguishing it from other linkage isomers. Together, these analyses verify the absolute chemical purity and precise structural identity of the final product.
Publication Data
Journal: Frontiers in nutrition
DOI: 10.1038/s41598-020-57860-8
IF: 5.1
Published: 2018
Results: This study investigates how Bifidobacterium longum subsp. infantis (B. infantis), a key commensal bacterium in the infant gut, differentially metabolizes two structurally similar HMOs: LNT and LNnT. The authors conducted in vitro experiments, including growth assays, metabolite profiling, and transcriptomic analyses, to compare bacterial physiology when these HMOs serve as sole carbon sources. Results revealed that while LNT supports efficient growth, LNnT utilization is less efficient, prompting a metabolic shift characterized by increased secretion of formic acid and ethanol, alongside an altered acetate-to-lactate ratio. Gene expression data indicated distinct transcriptional responses, particularly in pathways involving glycosyl hydrolases and oligosaccharide transporters. Strain-level variations were observed, with some B. infantis isolates showing unique metabolic profiles. Additionally, cell culture experiments suggested that fermentation metabolites from HMO-grown bacteria may reduce inflammation. The research underscores how subtle structural differences in HMOs drive significant physiological changes in beneficial gut bacteria, potentially influencing infant health through host-microbial interactions.
Application
Bifidogenic Prebiotic Development
Used in the formulation research of high-end supplements designed to establish a healthy, Bifidobacterium-dominant gut microbiome in neonates and adults.
Pathogen Decoy Research
LNT acts as a receptor analogue that inhibits the binding of enteric pathogens, such as Rotavirus and Salmonella, to the human intestinal epithelium.
Immune System Priming
Researchers utilize our LNT to study the modulation of gut-associated lymphoid tissue (GALT) and the reduction of inflammatory cytokine production in the gut.
Necrotizing Enterocolitis (NEC) Prevention
LNT is a focus of clinical research aimed at protecting preterm infants from NEC by strengthening the intestinal barrier and promoting beneficial flora.
Advantages
Authentic Type I Structure
Our enzymes are specifically selected for β-1,3-galactosyltransferase activity, ensuring your LNT is structurally identical to the natural form, unlike Type II (LNnT), often used as a substitute.
High Molar Conversion
Utilizing optimized pathways, we achieve exceptional conversion rates of lactose to LNT, maximizing resource efficiency.
Selective Prebiotic Efficacy
Our LNT is validated for its ability to selectively promote the growth of B. infantis, the gold standard for infant gut health.
Reduced Downstream Complexity
By minimizing the accumulation of trisaccharide intermediates, we simplify the purification process, resulting in a more cost-effective final product.
Frequently Asked Questions
Customer Review
"The purity of LNT from CD BioGlyco is unparalleled. It allowed us to achieve clear, reproducible results in our Bifidobacterium colonization studies."
– Dr. K.L., Senior Scientist, Pediatric Nutrition
"CD BioGlyco's ability to scale production while maintaining strict structural integrity has made them an indispensable partner in our HMO development pipeline."
– Manager S.V., R&D Department
"We were particularly impressed with the NMR validation package. It provided the structural certainty we needed for our receptor-binding assays."
– Dr. M.T., Principal Investigator, Gastroenterology
Associated Services
Globotriose (Galα1,4Galβ1,4Glc) Production Service
High-purity synthesis for toxin-binding and therapeutic research.
Galβ1,4GlcNAcβ1,4GlcNAc Production Service
Synthesis of complex glycan backbones for pharmaceutical use.
Galα1,4Galβ1,4GlcNAc Production Service
Production of rare oligosaccharides for immunological applications.
CD BioGlyco is a global leader in the LNT production service, delivering the most abundant and critical neutral HMO core through cutting-edge synthetic glycobiology. By offering human-identical, high-purity LNT at scale, we empower our clients to innovate in the fields of infant nutrition, microbiome health, and therapeutic development. Our expertise ensures that your project is built on a foundation of structural precision and industrial reliability. To receive a detailed product specification sheet or to discuss a custom production project with our specialists, please contact us.
Reference
Özcan, E.; Sela, D.A. Inefficient metabolism of the human milk oligosaccharides lacto-N-tetraose and lacto-N-neotetraose shifts Bifidobacterium longum subsp. infantis physiology. Frontiers in nutrition. 2018, 5: 46. (Open Access)
For research use only. Not intended for any clinical use.
